Next generation sequencing: Paradigm shift in genetic testing

Joris Veltman, PhD
Department of Human Genetics
Radboud University Nijmegen Medical Centre
Nijmegen, The Netherlands
j.veltman@gen.umcn.nl
“Progress in science depends on new techniques, new discoveries, and new ideas, probably in that order.”

- Sydney Brenner, 2002 Nobel Prize Winner
Finding the genetic causes of disease

• Diploid human genome consists of ~6 billion nucleotides

• A mutation at 1 position can result in disease

• Two individuals differ at ~3 million nucleotide positions

**How can we reliably identify and interpret these variants in individual patients?**
Challenges in genetic diagnostics

- Clinically diagnosing genetic disease is an art, ordering the right genetic test is difficult
- Single gene tests are laborious to set-up & expensive
- Diseases can be caused by different types of genetic variation, requiring different tests
- The genetic cause of 1000s of rare diseases is unknown
- Common diseases are genetically heterogeneous & their genetic causes are largely unknown

No genetic diagnosis for majority of diseases
Role of genetics in medicine is limited
Need for simple, cheap & effective genetic diagnosis
Next generation sequencing: Simple, cheap & effective?

DNA from blood

Genome sequence with all variation

Important:
- Accuracy
- Speed
- Price
Lessons learned from exome sequencing in disease gene identification

- Exome sequencing is a robust approach that can be highly automated
- It is not difficult to interpret the data if you ask the right question and have bioinformatic expertise
- Success rate of exome sequencing 70-80%, determined largely by the quality of clinical collection & sequencing
- Sporadic diseases have become amenable to genetic disease research, no need for families!
- *De novo* mutations; Important cause of sporadic disease

Gilissen et al. EJHG 2012
Diagnostic next generation sequencing

- Where can NGS make the most difference now?
  Monogenic diseases with locus heterogeneity!
  ID, blindness, deafness, movement disorders,
  mitochondrial disease, hereditary cancers etc.

- What approach: target genesets, exome or genome?
  Set of disease genes is rapidly expanding
  Exome sequencing is a generic test, allows most flexibility
  Genome sequencing not high-throughput & affordable yet
Which NGS-test to choose: Targeted assays vs. Exome

**Targeted**
- Develop per (group of) diseases
- Can be optimized for “perfect“ disease gene screening
- Higher throughput
- Needs to be updated regularly
- Interpretation only once
- Only data on selected genes
- Cheaper as a single test
- More easy interpretation
- Lower diagnostic yield per test

**Exome**
- Generic test for all diseases
- May miss causative mutations in known disease genes
- Lower throughput
- Less updating required
- Data interpreted repeatedly
- Normal variation accumulates
- Chance for incidental findings
- More expensive as a single test
- More follow-up required
- Higher diagnostic yield per test

Nelen & Veltman, Pharmacogenomics 2012
NGS in diagnostics: The time is now!

- **This ESHG!**

  - Cockburn (Leeds): targeted BRCA1&2, TP53 etc. >1400 reports
  - Matthijs (Leuven): targeted BRCA1&2, 1500 reports
  - Dean (Bristol): targeted seq hypercholesterolemia genes, reports?
  - Bergmann (Ingelheim): targeted seq cilia-related genes, reports?
  - Black (Manchester): targeted RP-genes, validation phase

- Biesecker (NIH, Bethesda): diagnostic exome seq, 580 reports
- Nelen (Nijmegen): diagnostic exome seq, 300 reports
- Stray-Petersen (Oslo, Houston): diagnostic exome seq, reports?
Some personal thoughts

- Do not only set-up tests for one or two years, try to look a bit further down the road if possible
- Don’t wait for tests to become perfect, optimization will have to happen during the implementation phase
- Europe can lead in this effort because of excellent link between research and diagnostics
- Proceed with care, openly discuss bottlenecks for reaching long-term goals, develop joint strategies
- Involve all stakeholders early in the process
- Genome sequencing will be the dominant diagnostic test in 5-10 years time
New Frontiers Symposium 2012
Personal Genomics

Sydney Brenner  James Lupski  Nicholas Katsanis  John Burn
Stylianos Antonarakis  Richard Durbin  Peter Holland  Jose Luis Gomez-Skarmeta

Nijmegen, NL
December 3&4 2012
Registration now open

www.ncmls.eu/newfrontiers2012  Radboud University Nijmegen  Medical Centre
Major challenges for clinical implementation of exomes & genomes

- NGS-sequencing is imperfect, technology needs to improve, costs need to go down
- Affordable & large-scale data storage
- User-friendly software to interpret enormous amounts of data
- International data sharing to improve understanding
- Appropriate counseling with informed consent
- Additional challenge: Dealing with “incidental findings”
- Approach towards re-analysis of negative exomes/genomes
- Education/training of laboratory personnel & clinicians
- Need to evaluate and demonstrate clinical utility
- Need for practical guidelines in a clinical setting